DMRA

Damora Therapeutics, Inc.

Price Chart

Latest Quote

$21.23

-0.19 (-0.89%)

Current Price

Previous Close	$21.42
Open	$21.71
Day High	$22.33
Day Low	$21.04
Volume	1,747,141

Fetched: 2026-06-21T12:27:52

Stock Information

Shares Outstanding	61.55M
Cash Equivalents	$532.90M
Net Income	$-235.09M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.31B
EPS (TTM)	$-2.68
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$906.33M
Income	$-235.09M
Book/sh	$6.29
Cash/sh	$8.66
Employees	7

Financial Ratios

Quick Ratio	22.42
Current Ratio	22.48

Returns & Margins

ROA	-14.70%
ROE	-89.50%

Ownership

Insider Ownership	7.69%
Institutional Ownership	91.09%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-10.22
P/B	3.38

Analyst Data

Recommendation	strong_buy
Target Price	$43.38

Technical Indicators

SMA20	$22.59
SMA50	$24.19
SMA200	$20.40
RSI	29.43
ATR	1.9949

Shares Float	41.22M
Short Float	2.66%
Short Ratio	3.83
Volatility	1.48
Rel Volume	3.93

Performance History

Week	-0.61%
Month	-11.69%
Quarter	+10.57%
6 Months	-29.23%
YTD	-2.70%
Year	+559.32%
3 Years	-59.94%
5 Years	-84.86%
10 Years	-94.34%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$21.23	1,747,100
2026-06-17	$21.42	259,100
2026-06-16	$20.59	397,100
2026-06-15	$20.07	629,000
2026-06-12	$20.78	207,200
2026-06-11	$21.36	313,200
2026-06-10	$20.15	531,800
2026-06-09	$20.96	462,100
2026-06-08	$20.91	302,100
2026-06-05	$21.01	523,500
2026-06-04	$22.31	458,600
2026-06-03	$22.33	318,600
2026-06-02	$22.95	288,700
2026-06-01	$24.85	307,400
2026-05-29	$24.88	846,800
2026-05-28	$24.84	303,000
2026-05-27	$25.21	222,400
2026-05-26	$25.89	346,100
2026-05-22	$25.30	166,300
2026-05-21	$24.86	255,200
2026-05-20	$24.15	180,000
2026-05-19	$24.04	249,500

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

📰 Latest News

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

Motley Fool • 2026-05-30T18:12:32Z

What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders

Simply Wall St. • 2026-05-08T21:30:38Z

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Insider Monkey • 2026-05-05T17:05:19Z

Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum

Simply Wall St. • 2026-05-05T14:10:14Z

Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says

MT Newswires • 2026-04-24T15:54:44Z

What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?

Zacks • 2026-04-20T16:00:02Z

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

Zacks • 2026-04-10T13:55:03Z

Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?

Simply Wall St. • 2026-04-01T12:18:52Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$210,872,000	$21,292,000	$36,457,000	$61,207,000
Other Income Expense	$-84,000	$-950,000	$-3,581,000	$-1,139,000
Net Non Operating Interest Income Expense	$1,167,000	$844,000	$1,689,000	$722,000
Operating Expense	$210,872,000	$21,292,000	$36,457,000	$61,207,000
General And Administrative Expense	$9,685,000	$10,499,000	$12,687,000	$13,001,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Net Interest Income	$1,167,000	$844,000	$1,689,000	$722,000
Interest Income	$1,167,000	$844,000	$1,689,000	$722,000
Normalized Income	$-209,755,000	$-20,489,000	$-34,768,000	$-60,485,000
Net Income From Continuing And Discontinued Operation	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Total Operating Income As Reported	$-210,872,000	$-22,260,000	$-39,905,000	$-61,207,000
Net Income Common Stockholders	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Net Income	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Net Income Including Noncontrolling Interests	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Net Income Continuous Operations	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Pretax Income	$-209,789,000	$-21,398,000	$-38,349,000	$-61,624,000
Special Income Charges	$0	$-968,000	$-3,384,000	$0
Interest Income Non Operating	$1,167,000	$844,000	$1,689,000	$722,000
Operating Income	$-210,872,000	$-21,292,000	$-36,457,000	$-61,207,000
Per Share
Diluted EPS	$-3.98	$-18.53	$-36.08	$-60.75
Basic EPS	$-3.98	$-18.53	$-36.08	$-60.75
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-210,754,000	$-20,161,000	$-32,046,000	$-59,578,000
Total Unusual Items	$-84,000	$-950,000	$-3,581,000	$-1,139,000
Total Unusual Items Excluding Goodwill	$-84,000	$-950,000	$-3,581,000	$-1,139,000
Reconciled Depreciation	$34,000	$181,000	$830,000	$490,000
EBITDA (Bullshit earnings)	$-210,838,000	$-21,111,000	$-35,627,000	$-60,717,000
EBIT	$-210,872,000	$-21,292,000	$-36,457,000	$-61,207,000
Diluted Average Shares	$1,363,005	$1,157,149	$1,062,873	$1,016,364
Basic Average Shares	$1,363,005	$1,157,149	$1,062,873	$1,016,364
Diluted NI Availto Com Stockholders	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Tax Provision	$50,000	$41,000	$0	-
Restructuring And Mergern Acquisition	$0	$968,000	$3,448,000	$0
Gain On Sale Of Security	$-84,000	$18,000	$-197,000	$-1,139,000
Research And Development	$201,187,000	$10,793,000	$23,770,000	$48,206,000
Selling General And Administration	$9,685,000	$10,499,000	$12,687,000	$13,001,000
Other Gand A	$9,685,000	$10,499,000	$12,687,000	$13,001,000
Gain On Sale Of Ppe	-	$0	$64,000	$0

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$240,380,000	$15,831,000	$32,331,000	$61,753,000
Total Assets	$260,527,000	$17,132,000	$38,227,000	$73,188,000
Total Non Current Assets	$104,000	$293,000	$1,453,000	$9,278,000
Current Assets	$260,423,000	$16,839,000	$36,774,000	$63,910,000
Other Current Assets	$125,000	$90,000	$85,000	$52,000
Current Deferred Assets	$1,198,000	$1,103,000	$1,046,000	$1,450,000
Prepaid Assets	$577,000	$590,000	$774,000	$805,000
Receivables	$899,000	$881,000	$1,718,000	$1,379,000
Taxes Receivable	$899,000	$881,000	$1,718,000	$1,379,000
Cash Cash Equivalents And Short Term Investments	$257,624,000	$14,175,000	$33,151,000	$60,224,000
Cash And Cash Equivalents	$257,624,000	$14,175,000	$21,465,000	$32,786,000
Other Non Current Assets	-	$163,000	$1,128,000	$2,279,000
Investmentin Financial Assets	-	-	$0	$5,832,000
Debt
Total Debt	$68,000	$73,000	$249,000	$804,000
Long Term Debt And Capital Lease Obligation	$53,000	$61,000	$66,000	$328,000
Current Debt And Capital Lease Obligation	$15,000	$12,000	$183,000	$476,000
Liabilities
Total Liabilities Net Minority Interest	$20,147,000	$1,301,000	$5,896,000	$11,435,000
Total Non Current Liabilities Net Minority Interest	$81,000	$104,000	$66,000	$328,000
Other Non Current Liabilities	$28,000	$43,000	-	-
Current Liabilities	$20,066,000	$1,197,000	$5,830,000	$11,107,000
Other Current Liabilities	$1,080,000	$476,000	$539,000	$539,000
Payables And Accrued Expenses	$18,529,000	$505,000	$4,121,000	$9,495,000
Payables	$17,665,000	$377,000	$1,702,000	$3,350,000
Other Payable	$17,221,000	-	-	-
Accounts Payable	$444,000	$377,000	$1,702,000	$3,350,000
Equity
Common Stock Equity	$-175,873,000	$14,471,000	$32,331,000	$61,753,000
Preferred Stock Equity	$416,253,000	$1,360,000	-	-
Total Equity Gross Minority Interest	$240,380,000	$15,831,000	$32,331,000	$61,753,000
Stockholders Equity	$240,380,000	$15,831,000	$32,331,000	$61,753,000
Gains Losses Not Affecting Retained Earnings	$802,000	$97,000	$380,000	$-244,000
Other Equity Adjustments	$802,000	$97,000	$380,000	$-244,000
Retained Earnings	$-487,363,000	$-277,524,000	$-256,085,000	$-217,736,000
Other
Ordinary Shares Number	$1,597,321	$1,316,989	$1,084,507	$1,026,095
Share Issued	$1,597,321	$1,316,989	$1,084,507	$1,026,095
Tangible Book Value	$-175,873,000	$14,471,000	$32,331,000	$61,753,000
Invested Capital	$-175,873,000	$14,471,000	$32,331,000	$61,753,000
Working Capital	$240,357,000	$15,642,000	$30,944,000	$52,803,000
Capital Lease Obligations	$68,000	$73,000	$249,000	$804,000
Total Capitalization	$240,380,000	$15,831,000	$32,331,000	$61,753,000
Additional Paid In Capital	$310,688,000	$291,898,000	$288,036,000	$279,733,000
Capital Stock	$416,253,000	$1,360,000	$0	$0
Common Stock	$0	$0	$0	$0
Preferred Stock	$416,253,000	$1,360,000	$0	$0
Long Term Capital Lease Obligation	$53,000	$61,000	$66,000	$328,000
Current Capital Lease Obligation	$15,000	$12,000	$183,000	$476,000
Pensionand Other Post Retirement Benefit Plans Current	$442,000	$204,000	$987,000	$597,000
Current Accrued Expenses	$864,000	$128,000	$2,419,000	$6,145,000
Net PPE	$104,000	$130,000	$325,000	$1,167,000
Accumulated Depreciation	$-72,000	$-50,000	$-29,000	$-62,000
Gross PPE	$176,000	$180,000	$354,000	$1,229,000
Other Properties	$176,000	$180,000	$354,000	$1,229,000
Other Short Term Investments	-	$0	$11,686,000	$27,438,000
Investments And Advances	-	-	$0	$5,832,000
Other Investments	-	-	-	$5,832,000
Available For Sale Securities	-	-	-	$5,832,000
Machinery Furniture Equipment	-	-	-	-

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-6,726,000	$-18,623,000	$-36,911,000	$-43,128,000
Operating Activities
Operating Cash Flow	$-6,726,000	$-18,623,000	$-36,911,000	$-42,932,000
Cash Flow From Continuing Operating Activities	$-6,726,000	$-18,623,000	$-36,911,000	$-42,932,000
Operating Gains Losses	$9,362,000	-	$-64,000	$70,000
Investing Activities
Investing Cash Flow	$-17,374,000	$11,650,000	$22,330,000	$12,384,000
Cash Flow From Continuing Investing Activities	$-17,374,000	$11,650,000	$22,330,000	$12,384,000
Capital Expenditure	-	-	-	$-196,000
Financing Activities
Issuance Of Capital Stock	$266,811,000	$0	$2,876,000	$507,000
Financing Cash Flow	$266,844,000	$0	$2,876,000	$507,000
Cash Flow From Continuing Financing Activities	$266,844,000	$0	$2,876,000	$507,000
Net Preferred Stock Issuance	$266,811,000	$0	-	-
Preferred Stock Issuance	$266,811,000	$0	-	-
Net Common Stock Issuance	-	$0	$2,876,000	$507,000
Common Stock Issuance	-	$0	$2,876,000	$507,000
Other
Income Tax Paid Supplemental Data	$5,000	$0	$0	$0
End Cash Position	$257,624,000	$14,175,000	$21,465,000	$32,786,000
Beginning Cash Position	$14,175,000	$21,465,000	$32,786,000	$62,563,000
Effect Of Exchange Rate Changes	$705,000	$-317,000	$384,000	$264,000
Changes In Cash	$242,744,000	$-6,973,000	$-11,705,000	$-30,041,000
Proceeds From Stock Option Exercised	$33,000	$0	-	-
Net Investment Purchase And Sale	$0	$11,650,000	$22,247,000	$12,580,000
Sale Of Investment	$0	$11,650,000	$48,184,000	$57,445,000
Net Business Purchase And Sale	$-17,374,000	$0	-	-
Purchase Of Business	$-17,374,000	$0	-	-
Change In Working Capital	$18,364,000	$-2,667,000	$-4,370,000	$11,937,000
Change In Other Current Liabilities	$-35,000	$-127,000	$-600,000	$-523,000
Change In Other Current Assets	$166,000	$970,000	$1,148,000	$-257,000
Change In Payables And Accrued Expense	$18,371,000	$-4,464,000	$-4,983,000	$6,485,000
Change In Accrued Expense	$1,099,000	$-3,139,000	$-3,335,000	$4,666,000
Change In Payable	$17,272,000	$-1,325,000	$-1,648,000	$1,819,000
Change In Account Payable	$17,272,000	$-1,325,000	$-1,648,000	$1,819,000
Change In Prepaid Assets	$-138,000	$954,000	$65,000	$6,232,000
Other Non Cash Items	$174,355,000	$1,993,000	$46,000	$58,000
Stock Based Compensation	$998,000	$3,239,000	$5,427,000	$5,571,000
Amortization Of Securities	$0	$70,000	$-431,000	$566,000
Depreciation Amortization Depletion	$34,000	$181,000	$830,000	$490,000
Depreciation And Amortization	$34,000	$181,000	$830,000	$490,000
Depreciation	$34,000	$181,000	$830,000	$490,000
Gain Loss On Investment Securities	$9,362,000	-	-	$70,000
Net Income From Continuing Operations	$-209,839,000	$-21,439,000	$-38,349,000	$-61,624,000
Purchase Of Investment	-	$0	$-25,937,000	$-44,865,000
Net PPE Purchase And Sale	-	$0	$83,000	$-196,000
Sale Of PPE	-	$0	$83,000	$0
Gain Loss On Sale Of PPE	-	$0	$-64,000	$0
Purchase Of PPE	-	-	$0	$-196,000

Fetched: 2026-06-19